CAR T-cell therapy for CD70-positive pediatric high-grade glioma
Part of Brain & nervous system, Cancer clinical trials.
This trial tests a new immune cell therapy (CAR T-cells) that targets a protein called CD70 found on some brain tumor cells. It is for children and young adults with newly diagnosed or recurrent high-grade glioma, including DIPG.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 4 and 30 years old (depending on the tumor type).
- Your tumor must test positive for CD70 (at least 5% of cells with low or higher staining).
- You must be able to walk or use a wheelchair due to stable neurological problems, with a performance score of 60% or higher.
- Your blood counts, kidney function, and liver function must be within a certain range.
- Any prior cancer treatments must have been finished at least 7–42 days before joining (depending on the drug).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immunotherapy called B7H3 IL-7Ra CAR T-cells for children with DIPG, a tough-to-treat brain tumor. The treatment is given directly into the fluid around the brain using a special catheter, and the goal is to see if it's safe and if it can help fight the tumor.
This trial tests a new CAR T cell therapy (BCB-276) for children and young adults with a type of brain tumor called DIPG. The therapy uses your own immune cells that are specially trained to attack the cancer.
This trial tests a special immune-cell therapy (GD2 CAR T cells) made for pediatric brain tumor patients. It uses a planned treatment plan and monitoring to see if the therapy is safe and can work against the tumor.
This Phase 1 study tests CAR T cells designed to target a marker called GD2 on brain tumors. It aims to see if the treatment is safe and whether it can shrink or control these tumors in children and young adults.
This Phase 1 trial tests a personalized immune-cell treatment (CAR T) delivered directly in the brain-area space using a catheter. It may help children and young adults with hard-to-treat (recurrent or refractory) diffuse midline brain tumors like DIPG/DMG when standard options aren’t working.
This trial tests a customized immune-cell treatment (CAR T cells) for adults with newly diagnosed glioblastoma (GBM) whose tumors have enough CD70 protein. If you qualify, the goal is to see whether this treatment can better control the cancer by targeting it in the brain.
Hear when a new High Grade Glioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.